医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EMBA Medical™ Limited Cleared to Market Hourglass™ Peripheral Embolization Plug in New Zealand

2015年11月18日 PM10:00
このエントリーをはてなブックマークに追加


 

DUBLIN

EMBA Medical Limited announced today that the company may now market its revolutionary peripheral embolization device in New Zealand due to the successful completion of the WAND (Web Assisted Notification of Devices) notification. In addition, the company announced completion of enrollment and release of 30-day follow-up data for the 10 patient EMBA Peripheral Embolization Device (EPED) Study conducted at Auckland Hospital.

EMBA Medical Limited completed the notification for the device, known as the Hourglass Peripheral Embolization Plug, through the New Zealand WAND database in conjunction with in-country sponsor Emergo on September 21, 2015.

George Wallace, CEO of EMBA Medical Limited, said, “This is the first integrated, over-the-wire device designed for peripheral embolization procedures. We believe that the Hourglassdevice will provide a new level of confidence, precision, and control for physicians performing peripheral embolization procedures.”

Interventional Radiologist Andrew Cragg, MD, co-inventor of the Hourglass device, commented, “The goal with over-the-wire design is to provide physicians with accurate, stent-like delivery of the device in the vessel. The device’s unique design was created to take advantage of natural hemodynamic forces to provide immediate, focal, stable occlusions.”

Patient interim results from the EPED Study demonstrated the benefits of both the hourglass design and over-the-wire delivery including:

  • 90 to 100% occlusion at 1 minute post-implant placement
  • Trackability rated as “easy” in 10 out of 10 procedures
  • PED occlusion at completion rated as “complete” in 100% of cases
  • Value of over-the-wire device placement rated as “very useful”

Dr. Andrew Holden, Director of Interventional Radiology at Auckland Hospital and Associate Professor of Radiology at Auckland University School of Medicine, is the primary investigator in the EPED clinical study. Following the first 10 cases with the 5F Hourglass Peripheral Embolization Plug, he commented, “We implanted the EMBA Hourglass in a variety of clinical embolization procedures. We found that the device was superior to coil embolization in many aspects including the ability to accurately deploy over a wire and obtain immediate occlusion with a single device in a wide range of vessel sizes.”

The Hourglass Peripheral Embolization Plug is a Class IIb medical device and is manufactured in the EMBA Medical Limited ISO-certified manufacturing facility in Miramar, Florida, USA. The device was awarded a CE certificate on July 10, 2015, enabling the company to pursue commercial activities in EU nations. The device has been submitted to the FDA and is currently under review.

About EMBA Medical Limited

EMBA Medical Limited is a Dublin, Ireland, domiciled medical device company that designs and develops innovative peripheral embolization technologies focused on improving safety, control, and outcomes. Malin Corporation plc, the Irish-based global life sciences company, is the lead investor in EMBA Medical. Intersect Partners, a medical device incubator with extensive experience in vascular interventions, is the developer of the technology. EMBA Medical Limited is located at Block 2 Harbour Square, Crofton Road, Dun Laoghaire, Dublin, Ireland. EMBA Medical and Hourglass are trademarks of EMBA Medical, Inc.

The company can be contacted at info@EMBAmedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005421/en/

CONTACT

EMBA Medical Limited
George Wallace, CEO
+1-954-604-6236
info@EMBAmedical.com
www.EMBAmedical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease